Form 4/A for OPRX OptimizeRx Corp
Accepted 2024-05-06 00:00:00 ET · period of report 2024-02-15 · accession 0001628280-24-020817 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-05-06 | 2024-02-15 | OPRX | Silvestro Stephen L | Chief Commercial Off | A - Grant | $0.00 | +7,750 | 16.9K | +85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | A | A | 7,750 | $0.00 | 16,906 | D | — | — | (F1) This Form 4 as originally filed reported in Table 1 a grant of Common Stock on March 15, 2024. However, this transaction occurred on February 15, 2024. (F2) Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on February 15, 2025, which is the first anniversary of the date of grant. (F3) A prior Form 4 filed by the Reporting Person failed to carry-forward previously owned shares, resulting in an understatement of the shares beneficially owned by the Reporting Person. The total amount beneficially owned has been adjusted to correct such inadvertent understatement. |